Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study
Retrospective study reveals discrepancies in evaluating remission and clinical success in myelofibrosis patients post-alloHCT, suggesting need for tailored response criteria.
Key Points
Discrepancies exist between clinician-defined and IWG-MRT/ELN response criteria for myelofibrosis post-transplant.
79% of patients were alive 24 months after allogeneic hematopoietic cell transplant, but only 54% met criteria for clinical complete response.
Clinical assessments indicated 58% of patients achieved clinical-CR by 6 months, underscoring early evaluation importance.
Findings call for the development of transplant-specific response criteria that include molecular assessments and treatment stratification.